Clinical Trials

Now Enrolling: The VITESSE Phase 3 Study for Peanut Allergy

The VITESSE phase 3 clinical research study is looking for children 4 to 7 years of age who have been diagnosed with peanut allergy and are currently following a strict peanut-free diet. Study doctors are testing an investigational drug patch (also called study drug patch) to learn how well it works and how safe it is in children with peanut allergy.

• What should I know about the VITESSE study?
  • To be eligible for this study, participants must be*:
  • 4 to 7 years of age
  • Diagnosed with peanut allergy
  • Currently following a strict peanut-free diet
    
    

*Other inclusion/exclusion criteria will apply.

• This study will consist of at least 12 study visits and 5 phone calls over a period of approximately 58 weeks (about 1 year)
• Participants will be randomly assigned (by chance) to receive the study drug patch or placebo patch (looks like the study drug but contains no active drug). Participants will have about a 67% (2 in 3) chance of receiving the study drug patch and about a 33% (1 in 3) chance of receiving the placebo patch
• The health and safety of participants will be monitored throughout the study
• Participant data and information will be kept confidential according to applicable laws for clinical research studies
• Study participants will receive all study-related procedures and the study drug patch or placebo patch at no cost
  
  

To learn more about the VITESSE phase 3 study and eligibility criteria, please visit VitesseAllergyStudy.com or ClinicalTrials.gov (identifier: NCT05741476).

Study sponsored by DBV Technologies

LEARN MORE

Is Eosinophilic Gastritis with or without Eosinophilic Duodenitis Affecting Your Daily Life?

You may be eligible for the Engage clinical study, which aims to investigate a study drug for EoG with or without EoD.

You may be eligible if you:

• Are ≥ 12 years old
• Have been diagnosed with EoG by endoscopic biopsy
• Have had at least 2 EoG episodes every week in the 8 weeks prior to joining the study (stomach pain, stomach cramping, nausea, bloating, early satiety, loss of appetite, vomiting, diarrhea)

There are other requirements to participate. To learn more about Engage, and whether it may be right for you, please visit the study website.

Protocol Number: R668-EGE-2213

© Regeneron Pharmaceuticals, Inc. All rights reserved.

LEARN MORE

Stay in the loop - get news and research updates straight to your inbox with our e-newsletters.

SIGN ME UP FOR UPDATES!